MSL10 mg

MSL is an opioid agonist analgesic indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Indications vary by formulation and are classified below by strength of evidence.

Established / FDA-approved uses

• Acute moderate-to-severe pain (immediate-release oral, injectable formulations) — e.g. post-surgical pain, trauma, acute medical pain.
• Chronic moderate-to-severe pain requiring around-the-clock, long-term opioid treatment (extended-release formulations), used only in opioid-tolerant patients.
• Cancer-related pain, including breakthrough pain, as part of a structured pain-management plan.

Guideline-supported / adjunct uses

• Palliative and end-of-life care, including symptomatic relief of severe dyspnea in advanced illness (WHO palliative care guidance), typically at low doses.
• Preoperative sedation and adjunct to anesthesia, to reduce anxiety and supplement anesthetic effect.
• Pain associated with acute myocardial infarction, as an adjunct to standard cardiac care, under close medical supervision.

MSL is not indicated for mild pain, as an as-needed (PRN) medicine for pain that is not expected to persist, or for use by opioid-non-tolerant patients in extended-release form.

Each formulation of Morphine Sulfate contains Morphine Sulfate as the active pharmaceutical ingredient, in strengths that vary by dosage form (e.g. immediate-release tablets, extended-release tablets/capsules, oral solution, and injectable solution for IV/IM/SC/epidural/intrathecal use). Please refer to the specific product label for the exact strength and excipients of the formulation dispensed.

MSL is a naturally derived opioid (phenanthrene) analgesic and the prototypical mu-opioid receptor agonist, used as the reference standard against which other opioid analgesics are compared. It is a Schedule-controlled substance available in immediate-release and extended-release oral forms, oral solution, and parenteral (injectable) forms for the treatment of moderate-to-severe pain.

MSL carries FDA boxed warnings for addiction, abuse and misuse potential; life-threatening respiratory depression; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; and the risk of fatal overdose from accidental ingestion, particularly by children. It should only be prescribed and used under close medical supervision.

MSL belongs to the therapeutic class of opioid analgesics (narcotic analgesics), specifically the phenanthrene class of natural opium alkaloids, and is classified as a mu-opioid receptor agonist.

Mechanism of action

Morphine Sulfate exerts its analgesic effect primarily by binding to and activating mu-opioid receptors in the central nervous system (brain and spinal cord), mimicking the action of endogenous opioid peptides. Activation of mu-receptors inhibits ascending pain-transmission pathways, alters the perception of and emotional response to pain, and produces generalized CNS depression. Morphine Sulfate also has minor activity at kappa and delta opioid receptors.

Pharmacokinetics

Morphine Sulfate undergoes extensive first-pass hepatic metabolism after oral administration (oral bioavailability roughly 20–40%), primarily via glucuronidation to morphine-3-glucuronide (inactive) and morphine-6-glucuronide (active, analgesically potent metabolite that accumulates in renal impairment). Onset of action is rapid after intravenous administration and somewhat delayed after oral or extended-release dosing. Elimination is mainly renal, as glucuronide conjugates.

• Immediate-release tablets/oral solution: may be taken with or without food; swallow tablets whole.
• Extended-release tablets/capsules must be swallowed whole — do not crush, chew, break, or dissolve, as this can cause rapid release and absorption of a potentially fatal dose.
• Injectable MSL is administered by a healthcare professional via IV, IM, SC, epidural, or intrathecal routes, with IV doses given slowly.
• Take exactly as prescribed, at the prescribed times; do not increase the dose or frequency without consulting the prescribing physician.

Only well-established, clinically significant interactions of MSL are listed below.

• CNS depressants (benzodiazepines, sedative-hypnotics, other opioids, general anesthetics, muscle relaxants, alcohol): concurrent use increases the risk of profound sedation, life-threatening respiratory depression, coma, and death. Avoid combination unless alternatives are inadequate; if combined, use the lowest effective doses with close monitoring.
• Monoamine oxidase inhibitors (MAOIs): concurrent use, or use within 14 days of MAOI discontinuation, may precipitate serotonin syndrome or unpredictable, severe potentiation of opioid effects; this combination should be avoided.
• Serotonergic drugs (SSRIs, SNRIs, triptans, certain other agents): increased risk of serotonin syndrome; monitor closely if co-administered.
• Mixed opioid agonist/antagonists or partial agonists (e.g. pentazocine, nalbuphine, butorphanol, buprenorphine): may reduce analgesic effect and/or precipitate opioid withdrawal symptoms in patients dependent on MSL.
• Anticholinergic drugs: increased risk of severe constipation, urinary retention, and paralytic ileus.
• Diuretics: MSL can reduce the efficacy of diuretics via release of antidiuretic hormone.

Very common / common

• Constipation (very common with regular use; often requires prophylactic laxative therapy)
• Nausea and vomiting
• Drowsiness, sedation, dizziness
• Dry mouth, sweating, pruritus (itching)
• Confusion, especially in elderly patients

Serious (require prompt medical attention)

• Life-threatening respiratory depression (see Precautions and Warnings)
• Severe hypotension, syncope
• Adrenal insufficiency (with prolonged use)
• Serotonin syndrome (with serotonergic drugs)
• Anaphylaxis/severe allergic reaction

Pregnancy

MSL should be used during pregnancy only if clearly needed and only if the potential benefit justifies the potential risk to the fetus; a physician must be consulted before use. Prolonged use of MSL during pregnancy can cause neonatal opioid withdrawal syndrome, which can be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts.

Lactation

MSL passes into breast milk. Breastfed infants of mothers taking MSL should be monitored for excess sedation and respiratory depression. Consult a physician before breastfeeding while using MSL; use is generally discouraged with higher or prolonged dosing.

Boxed warnings

• Addiction, abuse, and misuse potential: MSL exposes patients to risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk before prescribing and monitor regularly.
• Life-threatening respiratory depression: risk is greatest during initiation of therapy or following a dose increase; monitor closely, especially during the first 24–72 hours.
• Neonatal opioid withdrawal syndrome: with prolonged use during pregnancy (see Pregnancy and Lactation).
• Accidental ingestion: accidental ingestion of even one dose, especially by children, can result in a fatal overdose. Store securely out of reach of children and others.

Other precautions

• Tolerance and physical dependence: expected with regular use and are not the same as addiction; abrupt discontinuation after prolonged use can cause a withdrawal syndrome — taper gradually under medical supervision.
• Hypotension: use with caution in hypovolemic patients or those on drugs affecting blood pressure control.
• Head injury / increased intracranial pressure: may obscure the clinical course and increase intracranial pressure via CO2 retention; use with extreme caution.
• Biliary tract disease / pancreatitis: may cause spasm of the sphincter of Oddi.
• Respiratory disease: use with caution in COPD, sleep apnea, or compromised respiratory reserve due to increased risk of respiratory depression.
• Seizure disorders: may aggravate seizures in patients with a seizure disorder.
• May impair mental and/or physical ability required for driving or operating machinery.
• Controlled substance — must be prescribed, dispensed, and used according to local drug-control regulations.

Overdose of MSL is a medical emergency. Signs include pinpoint (miotic) pupils, severe respiratory depression or apnea, extreme drowsiness progressing to stupor or coma, cold and clammy skin, hypotension, and bradycardia; it can be fatal.

If overdose is suspected, seek immediate emergency medical attention or contact emergency services / poison control right away. Do not attempt to manage a suspected overdose at home. Treatment requires professional medical care, which may include airway support, ventilatory assistance, and administration of an opioid antagonist (naloxone) by trained personnel.

Store at room temperature (below 30°C), away from light and moisture. Keep in a secure location out of reach and sight of children and anyone for whom it is not prescribed, given the risk of fatal accidental ingestion. Dispose of unused medicine safely, as directed by a pharmacist.

Elderly

Start at the lower end of the dosing range for MSL due to increased sensitivity to sedative and respiratory effects; titrate cautiously.

Renal impairment

Active metabolites accumulate; reduce dose and/or extend dosing interval, with close monitoring (see Dosage and Administration).

Hepatic impairment

Reduce dose and titrate slowly with close monitoring.

Respiratory disease

Use with caution and close monitoring in patients with COPD, sleep apnea, or reduced respiratory reserve.

Pregnancy and lactation

See Pregnancy and Lactation section.

For acute pain, MSL should be used at the lowest effective dose for the shortest duration consistent with treatment goals, with regular reassessment of ongoing need. For chronic, cancer, or palliative pain, duration is individualized and guided by regular clinical reassessment of pain control, function, and risk of adverse effects, typically as part of a broader pain-management plan with periodic review by the prescribing physician.

Morphine Sulfate belongs to the opioid analgesic (narcotic analgesic) drug class, specifically a phenanthrene-derivative, mu-opioid receptor agonist, and is regulated as a controlled substance.

Morphine Sulfate acts primarily as an agonist at mu-opioid receptors in the central nervous system, inhibiting pain-signal transmission and altering the perception of and emotional response to pain, with additional minor activity at kappa and delta opioid receptors.

C

Use of MSL in children requires individualized, weight-based dosing under the supervision of a physician experienced in pediatric pain management, with careful titration and close monitoring for respiratory depression, particularly in neonates and infants who may have altered clearance. Extended-release formulations of MSL are generally not recommended for opioid-non-tolerant pediatric patients. Safety and efficacy of specific MSL formulations have not been established in neonates and in children below the age ranges specified in the product labeling; use in these groups should follow specialist pediatric/palliative-care guidance only.